Editas Medicine has been granted a patent for a genome editing system utilizing guide RNAs and CRISPR technology to alter specific portions of a target nucleic acid. The system includes specific sequences for targeting domains and an RNA-guided nuclease to create double-stranded breaks for genetic modifications. GlobalData’s report on Editas Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Editas Medicine, CRISPR genome editing was a key innovation area identified from patents. Editas Medicine's grant share as of May 2024 was 14%. Grant share is based on the ratio of number of grants to total number of patents.
Genome editing system for altering target nucleic acid
A recently granted patent (Publication Number: US11963982B2) discloses a genome editing system designed to target the BCL11A gene for the purpose of creating specific alterations in the gene. The system comprises a combination of guide RNAs (gRNAs) with targeting domains that are closely matched to specific sequences within the BCL11A gene, along with an RNA-guided nuclease. By associating within the target region of the gene, this system generates a double-stranded break (DSB) to induce an indel in the target nucleic acid, ultimately leading to the desired genetic modifications.
Furthermore, the patent also covers methods for altering cells and treating ß-hemoglobinopathies in subjects by administering modified hematopoietic cells. These methods involve the same genome editing system with closely matched gRNAs and an RNA-guided nuclease to induce targeted genetic alterations in the BCL11A gene. By creating indels in specific regions of the gene, these methods aim to address genetic abnormalities associated with ß-hemoglobinopathies. The use of chemically synthesized gRNAs adds a practical aspect to the implementation of these methods, making them potentially more accessible and efficient in a clinical setting.
To know more about GlobalData’s detailed insights on Editas Medicine, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
